Downloads: 288

Files in This Item:
File Description SizeFormat 
2162-3619-3-6.pdf806.69 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNagai, Yuyaen
dc.contributor.authorKawahara, Masahiroen
dc.contributor.authorSugino, Norikoen
dc.contributor.authorShimazu, Yayoien
dc.contributor.authorHishizawa, Masakatsuen
dc.contributor.authorYamashita, Kouheien
dc.contributor.authorKadowaki, Norimitsuen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.alternative河原, 真大ja
dc.date.accessioned2014-04-08T04:10:14Z-
dc.date.available2014-04-08T04:10:14Z-
dc.date.issued2014-02-17-
dc.identifier.issn2162-3619-
dc.identifier.urihttp://hdl.handle.net/2433/185221-
dc.description.abstractHere we report on a case of Philadelphia chromosome positive B lymphoblastic leukemia (Ph+ALL), which developed following a long duration of essential thrombocythemia (ET). A mutational analysis of Janus Kinase 2 (JAK2) revealed that the V617F mutation was present in granulocytes and in hematopoietic stem and progenitor cells (HSPCs), but not in the CD34+CD19+ population that mostly consists of Ph+ALL cells, indicating that this Ph+ALL clone did not originate from the ET clone carrying the JAK2-V617F mutation. The minor BCR-ABL1 fusion was detected not only in the CD34+CD19+ population but also in HSPCs and granulocytes, indicating that the Philadelphia chromosome was acquired in an early hematopoietic stage at least prior to the commitment to B cell development. Upon dasatinib treatment, the minor BCR-ABL1 transcript rapidly disappeared in HSPCs but persisted in the CD34+CD19+ population. A relapse of Ph+ALL occurred nine months later without the disappearance of the minor BCR-ABL1 transcript in the bone marrow cells during the treatment course, suggesting that a resistant Ph+ALL clone may have arisen or been selected in the committed B cells rather than in HSPCs. This case report may partly contribute to filling the gap between previous data acquired from mice experiments and the phenomenon in real patients.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central Ltd.en
dc.rights© 2014 Nagai et al.; licensee BioMed Central Ltd.en
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectJAK2-V617Fen
dc.subjectMyeloproliferative neoplasmsen
dc.subjectBCR-ABL1en
dc.subjectLymphoblastic leukemiaen
dc.subjectTyrosine kinase inhibitoren
dc.subjectResistant cloneen
dc.titleA case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation.en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleExperimental hematology & oncologyen
dc.identifier.volume3-
dc.identifier.issue1-
dc.relation.doi10.1186/2162-3619-3-6-
dc.textversionpublisher-
dc.identifier.artnum6-
dc.identifier.pmid24528501-
dcterms.accessRightsopen access-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.